S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
S&P 500   5,078.18 (+0.17%)
DOW   38,972.41 (-0.25%)
QQQ   437.60 (+0.24%)
AAPL   182.63 (+0.81%)
MSFT   407.48 (-0.01%)
META   487.05 (+1.10%)
GOOGL   138.88 (+0.95%)
AMZN   173.54 (-0.68%)
TSLA   199.73 (+0.17%)
NVDA   787.01 (-0.49%)
NIO   5.78 (+2.30%)
AMD   178.00 (+1.13%)
BABA   77.68 (+1.53%)
T   16.84 (+1.39%)
F   12.01 (+0.50%)
MU   91.85 (+2.67%)
CGC   3.53 (+1.73%)
GE   153.99 (-0.50%)
DIS   109.45 (+1.64%)
AMC   4.81 (+7.86%)
PFE   26.89 (-1.07%)
PYPL   60.16 (+1.40%)
XOM   104.03 (-0.21%)
NYSE:ANVS

Annovis Bio (ANVS) Stock Price, News & Analysis

$9.78
+0.91 (+10.26%)
(As of 02/27/2024 ET)
Today's Range
$8.70
$9.88
50-Day Range
$8.87
$19.62
52-Week Range
$5.42
$23.89
Volume
266,758 shs
Average Volume
298,814 shs
Market Capitalization
$103.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.25

Annovis Bio MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
250.2% Upside
$34.25 Price Target
Short Interest
Bearish
17.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.30) to ($3.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.61 out of 5 stars

Medical Sector

686th out of 945 stocks

Pharmaceutical Preparations Industry

299th out of 415 stocks


ANVS stock logo

About Annovis Bio Stock (NYSE:ANVS)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

ANVS Stock Price History

ANVS Stock News Headlines

Annovis Bio Inc (ANVS)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Annovis Bio Inc Ordinary Shares ANVS
Annovis Bio Inc Ordinary Shares
Annovis Bio to Participate in the 139th Yale CEO Summit
See More Headlines
Receive ANVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Annovis Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
2/27/2024
Next Earnings (Estimated)
4/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.25
High Stock Price Target
$36.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+286.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-25,330,000.00
Pretax Margin
-74,496.43%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.47 per share

Miscellaneous

Free Float
6,528,000
Market Cap
$93.84 million
Optionable
Optionable
Beta
1.65
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Maria L. Maccecchini Ph.D. (Age 73)
    Founder, CEO, President & Executive Director
    Comp: $965.6k
  • Mr. Henry Hagopian III (Age 56)
    M.B.A., Chief Financial Officer
    Comp: $510.05k
  • Dr. Cheng Fang Ph.D.
    Senior Vice President of Research & Development
  • Ms. Eve M. Damiano M.S.
    RAC, Senior Vice President of Regulatory Operations
  • Ms. Melissa Gaines
    Senior Vice President of Clinical Operations














ANVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Annovis Bio stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Annovis Bio in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ANVS shares.
View ANVS analyst ratings
or view top-rated stocks.

What is Annovis Bio's stock price target for 2024?

4 brokers have issued 1 year price targets for Annovis Bio's shares. Their ANVS share price targets range from $30.00 to $36.00. On average, they anticipate the company's stock price to reach $34.25 in the next twelve months. This suggests a possible upside of 250.2% from the stock's current price.
View analysts price targets for ANVS
or view top-rated stocks among Wall Street analysts.

How have ANVS shares performed in 2024?

Annovis Bio's stock was trading at $18.70 at the beginning of the year. Since then, ANVS stock has decreased by 47.7% and is now trading at $9.78.
View the best growth stocks for 2024 here
.

Are investors shorting Annovis Bio?

Annovis Bio saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 1,310,000 shares, an increase of 33.6% from the January 15th total of 980,200 shares. Based on an average daily trading volume, of 306,800 shares, the short-interest ratio is currently 4.3 days. Currently, 17.2% of the company's shares are short sold.
View Annovis Bio's Short Interest
.

When is Annovis Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024.
View our ANVS earnings forecast
.

How were Annovis Bio's earnings last quarter?

Annovis Bio, Inc. (NYSE:ANVS) announced its quarterly earnings data on Wednesday, November, 8th. The company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by $0.53.

What other stocks do shareholders of Annovis Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Annovis Bio investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), KushCo (KSHB), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Auxly Cannabis Group (CBWTF), Novan (NOVN), Sorrento Therapeutics (SRNE), CNBX Pharmaceuticals (CNBX) and Enerplus (ERF).

When did Annovis Bio IPO?

(ANVS) raised $10 million in an initial public offering (IPO) on Wednesday, January 29th 2020. The company issued 1,400,000 shares at a price of $6.00-$8.00 per share. ThinkEquity (a division of Fordham Financial Management, Inc. ) acted as the underwriter for the IPO.

Who are Annovis Bio's major shareholders?

Annovis Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.19%), Northern Trust Corp (0.27%), Merit Financial Group LLC (0.21%), GTS Securities LLC (0.00%), Dimensional Fund Advisors LP (0.10%) and Wealthspire Advisors LLC (0.10%). Insiders that own company stock include Claudine Bruck, Maria-Luisa Maccecchini and Reid Mccarthy.
View institutional ownership trends
.

How do I buy shares of Annovis Bio?

Shares of ANVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:ANVS) was last updated on 2/27/2024 by MarketBeat.com Staff